SecBot SecBot
PRESS-RELEASE ·Filed Aug 3, 2026

ORIC

ORIC Pharmaceuticals
NEUTRAL
Impact 5/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The slight EPS miss is secondary to the positive pipeline catalysts. Focus on the upcoming enozertinib data at ESMO October 2026 and the rinzimetostat program update in 2H 2026. The Bayer collaboration strengthens the Phase 3 trial setup without diluting ORIC's rights. Monitor cash burn rate relative to the runway into 2H 2028 and any further ATM activity.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

ORIC drug pipeline →

rinzimetostat

▲ Bullish Named in this press release
Impact
Phase
Phase 3
Time to market
If Phase 3 data is positive (expected 2H 2026), regulatory filing could follow in 2027, with potential FDA approval in 2028 at the earliest.
Next catalyst
None dated

What to watchWatch for rinzimetostat Phase 3 data readout expected in 2H 2026 (Himalayas-1 trial in mCRPC). Positive data would be a major catalyst for ORIC stock given rinzimetostat is the company's lead pipeline asset. The Bayer darolutamide collaboration strengthens the trial design without cost to ORIC.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.47
T+0 close · Aug 3, 2026 · via day close
Latest settled
−33.18%
T+60 · $9.00
Vs SPY
−32.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 4 $13.47entry
  2. T+1 · 3mo ago −4.01%α −3.81% · $12.93
  3. T+5 · 3mo ago +1.93%α +2.03% · $13.73
  4. T+20 · 3mo ago −4.31%α −3.07% · $12.89
  5. T+60 · 20d ago −33.18%α −32.97% · $9.00
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ORIC reported Q2 2026 net loss of $(0.38) per share, missing consensus of $(0.36) by $0.02. The operational highlight is the initiation of Himalayas-1, a global Phase 3 trial for rinzimetostat in metastatic castration-resistant prostate cancer, and a clinical collaboration with Bayer for darolutamide supply. Cash runway extends into 2H 2028, with key data catalysts expected in 2H 2026.

Key Financial Metrics

EPS
−$0.38
est −$0.36 · -5.6%
Revenue
$0.00
est $0.00 · 0.0%
Rating
miss

Key Facts

  • Q2 2026 net loss $(0.38)/share vs consensus $(0.36), a -5.6% miss
  • Initiated global Phase 3 registrational trial Himalayas-1 for rinzimetostat in mCRPC
  • Entered clinical trial collaboration with Bayer to receive darolutamide at no cost for Himalayas-1
  • Cash and investments $387.6M, expected runway into 2H 2028
  • R&D expenses $36.3M, up 19% YoY due to rinzimetostat advancement
  • Raised $59.9M via ATM in Q1 2026 from healthcare specialist funds
  • Enozertinib 1L EGFR atypical monotherapy data expected at ESMO October 2026

Financial Impact

Net loss of $41.5M for Q2 2026, versus $36.4M in Q2 2025; EPS miss of $0.02 relative to consensus

epsresearch and development expensescash runway

Risk Factors

  • Clinical trial risk for rinzimetostat Phase 3 (Himalayas-1) given competitive prostate cancer landscape
  • Dilution risk from potential further ATM drawdowns
  • Cash burn increasing as R&D expands with Phase 3 costs

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3337877

Track record

12 reports on ORIC

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today Press Release Neutral 5/10 Entry $7.52 Now $7.52 −0.00% settles Nov 24
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $7.59 Now $7.52 −0.92% settles Nov 23
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.72 Now $7.52 −2.59% settles Nov 23
  4. Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $8.91 Now $7.52 −15.60% settles Nov 17
  5. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $13.17 to $9.24 Now $7.52 −42.90% ▼ −29.84% −29.28% vs SPY
  6. Oct 5, 20266w ago Press Release Bullish 6/10 Entry $11.98 to $11.31 Now $7.52 −37.23% ▼ −5.59% −5.45% vs SPY
  7. Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $12.49 to $11.81 Now $7.52 −39.79% ▼ −5.44% −5.87% vs SPY
  8. Aug 3, 202615w ago Press Release Neutral 5/10 Viewing Entry $13.47 to $13.73 Now $7.52 −44.17% ▲ +1.93% +2.03% vs SPY
  9. Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.91 to $10.16 Now $7.52 −15.60% ▲ +13.97% +12.96% vs SPY
  10. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $7.82 to $8.63 Now $7.52 −3.84% ▲ +10.36% +9.92% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 3, 2026